The hygiene hypothesis: current perspectives and future therapies

被引:120
|
作者
Stiemsma, Leah T. [1 ,2 ]
Reynolds, Lisa A. [3 ]
Turvey, Stuart E. [1 ,2 ,4 ]
Finlay, B. Brett [1 ,3 ,5 ]
机构
[1] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC, Canada
[2] Univ British Columbia, Child & Family Res Inst, Vancouver, BC, Canada
[3] Univ British Columbia, Michael Smith Lab, Vancouver, BC, Canada
[4] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada
[5] Univ British Columbia, Dept Biochem & Mol, Vancouver, BC, Canada
来源
基金
加拿大健康研究院;
关键词
inflammatory bowel disease; microbiota; helminths; atopic disease; type; 1; diabetes;
D O I
10.2147/ITT.S61528
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Developed countries have experienced a steady increase in atopic disease and disorders of immune dysregulation since the 1980s. This increase parallels a decrease in infectious diseases within the same time period, while developing countries seem to exhibit the opposite effect, with less immune dysregulation and a higher prevalence of infectious disease. The "hygiene hypothesis", proposed by Strachan in 1989, aimed to explain this peculiar generational rise in immune dysregulation. However, research over the past 10 years provides evidence connecting the commensal and symbiotic microbes (intestinal microbiota) and parasitic helminths with immune development, expanding the hygiene hypothesis into the "microflora" and "old friends" hypotheses, respectively. There is evidence that parasitic helminths and commensal microbial organisms co-evolved with the human immune system and that these organisms are vital in promoting normal immune development. Current research supports the potential for manipulation of the bacterial intestinal microbiota to treat and even prevent immune dysregulation in the form of atopic disease and other immune-mediated disorders (namely inflammatory bowel disease and type 1 diabetes). Both human and animal model research are crucial in understanding the mechanistic links between these intestinal microbes and helminth parasites, and the human immune system. Pro-, pre-, and synbiotic, as well as treatment with live helminth and excretory/secretory helminth product therapies, are all potential therapeutic options for the treatment and prevention of these diseases. In the future, therapeutics aimed at decreasing the prevalence of inflammatory bowel disease, type 1 diabetes, and atopic disorders will likely involve personalized microbiota and/or helminth treatments used early in life.
引用
收藏
页码:143 / 156
页数:14
相关论文
共 50 条
  • [41] Current research and future therapies
    Andersson, KE
    Burnett, AL
    Chen, KK
    Christ, GJ
    Rampin, O
    Stief, C
    [J]. ERECTILE DYSFUNCTION, 2000, : 141 - 203
  • [42] CURRENT AND FUTURE ASTHMA THERAPIES
    Kandeel, M.
    Balaha, M.
    Inagaki, N.
    Kitade, Y.
    [J]. DRUGS OF TODAY, 2013, 49 (05) : 325 - 339
  • [43] Onychomycosis: Current and Future Therapies
    Lipner, Shari
    Scher, Richard K.
    [J]. CUTIS, 2014, 93 (02): : 60 - 63
  • [44] Current and future therapies for gout
    Pascart, Tristan
    Richette, Pascal
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1201 - 1211
  • [45] Current and future therapies for myelofibrosis
    Asher, Samir
    McLornan, Donal P.
    Harrison, Claire N.
    [J]. BLOOD REVIEWS, 2020, 42
  • [46] The hygiene hypothesis at a glance: Early exposures, immune mechanism and novel therapies
    Alexandre-Silva, Gabriel M.
    Brito-Souza, Pablo A.
    Oliveira, Ana C. S.
    Cerni, Felipe A.
    Zottich, Umberto
    Pucca, Manuela B.
    [J]. ACTA TROPICA, 2018, 188 : 16 - 26
  • [47] Medullary Thyroid Cancer-Current Treatment Strategy, Novel Therapies and Perspectives for the Future
    Sugawara, Masahiro
    Ly, Tran
    Hershman, Jerome M.
    [J]. HORMONES & CANCER, 2012, 3 (5-6): : 218 - 226
  • [48] Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
    Monica Margoni
    Paolo Preziosa
    Massimo Filippi
    Maria A. Rocca
    [J]. Journal of Neurology, 2022, 269 : 1316 - 1334
  • [49] Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
    Margoni, Monica
    Preziosa, Paolo
    Filippi, Massimo
    Rocca, Maria A.
    [J]. JOURNAL OF NEUROLOGY, 2022, 269 (03) : 1316 - 1334
  • [50] Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review
    Gupta, Sudeep
    Nag, Shona
    Aggarwal, Shyam
    Rauthan, Amit
    Warrier, Narayanankutty
    [J]. JOURNAL OF OVARIAN RESEARCH, 2019, 12 (01)